Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Siltuximab for CRS Prophylaxis in RRMM
NCT06352866Phase 2Withdrawn
- Start
- Jan 2025
- Primary completion
- Apr 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of siltuximab in cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS). Planned start Jan 2025; status: withdrawn.
02
Drugs
siltuximab
03
Conditions
cytokine release syndrome (CRS)immune effector cell-associated neurotoxicity syndrome (ICANS)
Beyond the preview
Go deeper on NCT06352866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06352866.